262 related articles for article (PubMed ID: 30138689)
21. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.
Mallat A; Zafrani ES; Metreau JM; Dhumeaux D
Dig Dis Sci; 1997 Jul; 42(7):1486-8. PubMed ID: 9246051
[TBL] [Abstract][Full Text] [Related]
22. [Terbinafine and cholestatic hepatitis].
Tejada García M; Llvona Hevia AM; Martín Arias L; García-Pando AC
Med Clin (Barc); 1997 Sep; 109(9):356. PubMed ID: 9379769
[No Abstract] [Full Text] [Related]
23. Terbinafine-induced hepatic dysfunction.
Chambers WM; Millar A; Jain S; Burroughs AK
Eur J Gastroenterol Hepatol; 2001 Sep; 13(9):1115-8. PubMed ID: 11564966
[TBL] [Abstract][Full Text] [Related]
24. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
[TBL] [Abstract][Full Text] [Related]
25. Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
Li YJ; Phillips EJ; Dellinger A; Nicoletti P; Schutte R; Li D; Ostrov DA; Fontana RJ; Watkins PB; Stolz A; Daly AK; Aithal GP; Barnhart H; Chalasani N;
Hepatology; 2021 Jan; 73(1):268-281. PubMed ID: 32270503
[TBL] [Abstract][Full Text] [Related]
26. Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series.
Heidemann LA; Navarro VJ; Ahmad J; Hayashi PH; Stolz A; Kleiner DE; Fontana RJ
Dig Dis Sci; 2016 Sep; 61(9):2741-8. PubMed ID: 27142670
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.
Russo MW; Hoofnagle JH; Gu J; Fontana RJ; Barnhart H; Kleiner DE; Chalasani N; Bonkovsky HL
Hepatology; 2014 Aug; 60(2):679-86. PubMed ID: 24700436
[TBL] [Abstract][Full Text] [Related]
28. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy.
Tsung I; Dolan R; Lao CD; Fecher L; Riggenbach K; Yeboah-Korang A; Fontana RJ
Aliment Pharmacol Ther; 2019 Oct; 50(7):800-808. PubMed ID: 31309615
[TBL] [Abstract][Full Text] [Related]
29. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus.
Kuzushita N; Hayashi N; Moribe T; Katayama K; Kanto T; Nakatani S; Kaneshige T; Tatsumi T; Ito A; Mochizuki K; Sasaki Y; Kasahara A; Hori M
Hepatology; 1998 Jan; 27(1):240-4. PubMed ID: 9425943
[TBL] [Abstract][Full Text] [Related]
30. Concurrent terbinafine-induced acute generalised exanthematous pustulosis and hepatitis.
Carnio LR; Johnson Shaw ME; Schnur J; Casadesus D
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462036
[TBL] [Abstract][Full Text] [Related]
31. [Clinic-epidemiological significance of drug hepatotoxicity in liver disease consultation].
Jmelnitzky AC; Guidi M; Bologna A; Viola M; Soccini C; Barbero R; Belloni P; Apraiz M
Acta Gastroenterol Latinoam; 2000; 30(2):77-84. PubMed ID: 10925723
[TBL] [Abstract][Full Text] [Related]
32. A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.
Kumar K; Gill A; Shafei R; Wright JL
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25480138
[TBL] [Abstract][Full Text] [Related]
33. [Hepatitis attributed to the use of terbinafine].
Boldewijn OY; Ottervanger JP; Mostart CM; Janssens AR; Calame J; Jonkers GJ
Ned Tijdschr Geneeskd; 1996 Mar; 140(12):669-72. PubMed ID: 8668241
[TBL] [Abstract][Full Text] [Related]
34. [Terbinafine induced hepatitis with persistent cholestasis].
Gendre G; Buclin T; Morard I; Fontannaz J; Berney JL
Rev Med Suisse; 2008 Mar; 4(149):736-9. PubMed ID: 18472735
[No Abstract] [Full Text] [Related]
35. HLA-B*35:01 and Green Tea-Induced Liver Injury.
Hoofnagle JH; Bonkovsky HL; Phillips EJ; Li YJ; Ahmad J; Barnhart H; Durazo F; Fontana RJ; Gu J; Khan I; Kleiner DE; Koh C; Rockey DC; Seeff LB; Serrano J; Stolz A; Tillmann HL; Vuppalanchi R; Navarro VJ;
Hepatology; 2021 Jun; 73(6):2484-2493. PubMed ID: 32892374
[TBL] [Abstract][Full Text] [Related]
36. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN].
Halegoua-DeMarzio D; Navarro V; Ahmad J; Avula B; Barnhart H; Barritt AS; Bonkovsky HL; Fontana RJ; Ghabril MS; Hoofnagle JH; Khan IA; Kleiner DE; Phillips E; Stolz A; Vuppalanchi R
Am J Med; 2023 Feb; 136(2):200-206. PubMed ID: 36252717
[TBL] [Abstract][Full Text] [Related]
37. A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage.
Kim JS; Jang YR; Lee JW; Kim JY; Jung YK; Chung DH; Kwon OS; Kim YS; Choi DJ; Kim JH
Korean J Hepatol; 2011 Sep; 17(3):229-32. PubMed ID: 22102391
[TBL] [Abstract][Full Text] [Related]
38. [Propafenon-induced cholestatic liver injury--a further example for allergic drug hepatitis (author's transl)].
Schuff-Werner P; Kaiser D; Lüders CJ; Berg PA
Z Gastroenterol; 1981 Oct; 19(10):673-9. PubMed ID: 6117993
[TBL] [Abstract][Full Text] [Related]
39. Terbinafine: Safety profile and monitoring in treatment of dermatophyte infections.
Sun CW; Hsu S
Dermatol Ther; 2019 Nov; 32(6):e13111. PubMed ID: 31595639
[No Abstract] [Full Text] [Related]
40. Terbinafine-induced cholestatic liver disease.
Lazaros GA; Papatheodoridis GV; Delladetsima JK; Tassopoulos NC
J Hepatol; 1996 Jun; 24(6):753-6. PubMed ID: 8835752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
